Nuformix plc (LSE:NFX) has appointed experienced corporate financier Tim Metcalfe as Non-Executive Chairman and Director as the pharmaceutical development company looks to strengthen its strategic and capital markets expertise.
Metcalfe will take up the roles with effect from 1 September 2026, succeeding Julian Gilbert, who will step down as Chairman and leave the board on 31 August for personal reasons. Gilbert will continue working with Nuformix in a consultancy capacity, providing continuity during the leadership transition.
The incoming chairman brings more than 30 years of experience across corporate finance, financial communications and the UK capital markets. He co-founded investor relations and financial PR consultancy IFC Advisory and has also held senior non-executive positions at other listed businesses.
Nuformix expects Metcalfe’s experience to support its efforts to generate shareholder value from NXP002, its lead development programme, as well as assist with ongoing partnering discussions and the company’s broader capital markets strategy.
The appointment comes as Nuformix continues to explore commercial opportunities across its fibrosis and oncology portfolio. Strengthening the board’s corporate finance and advisory expertise could prove particularly relevant as the company evaluates potential partnerships, licensing transactions and other strategic options for its development assets.
Gilbert’s continued involvement as a consultant is intended to provide additional support as Metcalfe assumes responsibility for chairing the board and helping guide the next stage of the company’s strategy.
Nuformix’s financial position nevertheless remains challenging, with an absence of recent revenue, continued losses and ongoing cash consumption weighing on its outlook. The company’s debt-free balance sheet provides some financial support, while shorter-term technical indicators have shown signs of stabilisation. Longer-term price trends and momentum remain mixed, however, and traditional valuation measures offer limited guidance while the business remains loss-making and does not pay a dividend.
About Nuformix Plc
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through the repurposing of existing drugs.
The company specialises in discovering, developing and patenting novel forms of known pharmaceutical compounds with altered or improved physical properties. This approach is designed to create differentiated products with new commercial applications while potentially reducing some of the development risks associated with entirely new drug candidates.
Nuformix is building a portfolio of preclinical assets with the aim of creating opportunities for partnerships and licensing transactions at relatively early stages of development.
Leave a Reply